The coronavirus has been spreading at a frantic pace, isolating families and snuffing out lives. As hunger and emotional contagion grip the nations, the hope of a containment also dims. No one has seen this enemy coming – the world has underestimated COVID-19.
Dr Poon Shi Hui, a consultant at the Department of Psychiatry at Singapore General Hospital, speaks to Roshini Claire Anthony on the different types of insomnia and the various management strategies deployed for each type.
Dr. Faith Chia Li-Ann, Dr. Paula P Tjokrosaputro, 20200224180010
Early diagnosis of RA is important such that treatment can be initiated early to prevent joint damage. Senior consultant Dr Faith Chia Li-Ann and senior resident Dr Paula P Tjokrosaputro from the Department of Rheumatology, Allergy and Immunology in Tan Tock Seng Hospital (TTSH), Singapore share their insights with Pearl Toh on the role of GPs in caring for patients with RA in the primary care setting.
This month we start a new column featuring everyday heroes such as yourself. MIMS Doctor speaks to GPs in various locations throughout Malaysia to learn about their life, their struggles and their hopes for the future. Dr Soo Tai Kang, who is also a treasurer of the Medical Practitioners Coalition Association of Malaysia (MPCAM) is the first person in our lineup.
Vertigo is not a diagnosis but rather a symptom of a myriad of conditions. It is a subset of dizziness or giddiness – a very common complaint among the ageing and often stressed out population. Dr Goh Xueying, Consultant, Department of Otolaryngology at the National University Hospital in Singapore, speaks with Audrey Abella to expound on how to identify vertigo red flags and to diagnose and manage appropriately.
In conjunction with World Pharmacists Day 2019, the Malaysian Pharmaceutical Society (MPS) and GlaxoSmithKline (GSK) Consumer Healthcare Sdn Bhd have reaffirmed a mutual commitment to high standards of patient safety in products and supply chains.
The interest in healthcare and medicine is evident from companies in fields unrelated to healthcare venturing into the scene. With this interest is the boom of healthcare facilities, both clinics and hospitals, being set up in the country. As of end 2017, Malaysia counted 200 private hospitals with 14,799 beds. [https://www.export.gov/article?id=Malaysia-Healthcare, Accessed on 18 November]
The recent launch of Sunway Medical Centre Velocity (SMCV) coincides with the boom of hospitals established in the country. However, its founding should not be seen as jumping on the bandwagon. Rather, the hospital is a carefully planned and executed venture. MIMS spoke to SMCV’s Chief Executive Officer, Wilson Choo, to get his insights on the establishment of SMCV and his vision for SMCV in the short and long term.
Bumrungrad International Hospital was founded in 1980 and has since grown to become one of the most reputable hospitals in the region. The recipient of numerous international awards and accreditations, Bumrungrad International is one of the largest private hospitals in Southeast Asia, catering to over 1.1 million patients from over 190 countries annually.
In an exclusive interview with MIMS, Kenny Lim, Chief Information Technology Officer of Bumrungrad International Hospital shared his views on how the hospital has continued to improve its services to patients with particular emphasis on the use of clinical decisions support tools.
Dr Dariusz P. Olszyna, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the importance of early detection to prevent the spread and complications related to sexually-transmitted infections (STIs).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.